CDT stock icon

Conduit Pharmaceuticals

0.1101 USD
+0.0036
3.38%
At close Oct 9, 4:00 PM EDT
Pre-market
0.1150
+0.0049
4.45%
1 day
3.38%
5 days
1.38%
1 month
-11.92%
3 months
-73.66%
6 months
-96.53%
Year to date
-97.65%
1 year
-94.95%
5 years
-98.94%
 

About: Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Employees: 7

0
Funds holding %
of 6,740 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

61% more funds holding

Funds holding: 18 [Q1] → 29 (+11) [Q2]

1.76% more ownership

Funds ownership: 2.2% [Q1] → 3.96% (+1.76%) [Q2]

48% less capital invested

Capital invested by funds: $5.96M [Q1] → $3.12M (-$2.84M) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for CDT.

Financial journalist opinion

Charts implemented using Lightweight Charts™